IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Aurobindo Pharma’s API business reports rise in sales, targets annual API sales of $700 million by 2016

1:04 AM MDT | August 20, 2013 | Deepti Ramesh

The active pharmaceutical ingredients (API) business of Aurobindo Pharma (Hyderabad, India) reports a 10.2% rise in sales, to 6.46 billion Indian rupees ($101 million), in the fiscal first quarter, ended 30 June, compared with the year-ago quarter. Cephalosporin accounted for Rs2.16 billion of the total API sales in the first quarter, semisynthetic penicillin (SSP) accounted for Rs2.22 billion, and nonbetalactam accounted for Rs2.08 billion. Earnings figures for the API business have not been disclosed. Aurobindo Pharma manufactures generic pharmaceuticals...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa